Celldex Therapeutics, Inc. (CLDX) vs Immunome, Inc. (IMNM)

Celldex Therapeutics, Inc. and Immunome, Inc. are both Biotechnology companies. Celldex Therapeutics, Inc. and Immunome, Inc. are of similar size ($2.6B and $2.5B). Immunome, Inc. grew revenue faster over the last twelve months: 16.7% against −88.3%. Immunome, Inc. has the higher net margin (0.00% vs −33,883.8%) and the lower return on invested capital (−3,323.0% vs 0.00%). Across the 16 metrics below, Immunome, Inc. leads on 11 and Celldex Therapeutics, Inc. on 5.

Valuation

Metric CLDX IMNM Biotechnology median
P/E n/m n/m 7.88
P/S 2,729.23 190.93 11.47
P/B 3.39 4.58 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1,923.07 149.65 10.73
Earnings yield (13.99%) (11.92%) (28.84%)
Free cash flow yield (10.00%) (9.11%) (23.03%)

Profitability

Metric CLDX IMNM Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (36,733.82%) 0.00% 0.00%
Net margin (33,883.77%) 0.00% 0.00%
Free cash flow margin (27,294.81%) 0.00% 0.00%
Return on equity (43.88%) (64.03%) (57.72%)
Return on assets (40.76%) (59.03%) (49.22%)
Return on invested capital 0.00% (3,322.99%) 0.00%

Growth

Metric CLDX IMNM Biotechnology median
Revenue growth (TTM) (88.27%) 16.74% 5.64%
EPS growth (last fiscal year) (59.18%) 51.40% —
Revenue growth, 5-year CAGR (26.93%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLDX IMNM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.82 15.08 4.73
Net debt to EBITDA 1.78 2.92 0.96

Dividend

Metric CLDX IMNM Biotechnology median
Dividend yield 2.16% — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CLDX IMNM Biotechnology median
Market cap 2.49b 2.56b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack